Neurocrine presented data on the CAHtalyst Adult study, which utilized Crenessity for managing classic Congenital Adrenal Hyperplasia (CAH), at the Endocrine Society's Annual Meeting.
3 reports, 2 independent
Updated Jul 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Neurocrine presented data on the CAHtalyst Adult study, which utilized Crenessity for managing classic Congenital Adrenal Hyperplasia (CAH), at the Endocrine Society's Annual Meeting.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaNeurocrine shares new one-year data from trial of Crenessity for CAH Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity (crinecerfont) for c
- PR NewswireNeurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Contro
- PR NewswireNeurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 One-year data from CAHtalyst™ Adult study demonstrated lasting r